Expanded Study of the HighLife 28mm Trans-septal Trans-catheter Mitral Valve in Patients With Moderate-severe or Severe Mitral Regurgitation and at High Surgical Risk

September 9, 2025 updated by: HighLife SAS
to evaluate the safety and performance of the HighLife 28mm transcatheter, trans-septal Mitral Valve in patients with moderate-severe or severe mitral regurgitation who are at high risk for surgical treatment.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

120

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • Australia
      • Adelaide, Australia, 5000
        • Recruiting
        • St. Andrew's Hospital
        • Contact:
        • Principal Investigator:
          • Joseph Montarello, MD
      • Brisbane, Australia
        • Recruiting
        • Princess Alexandra Hospital
        • Contact:
          • Anthony Camuglia, MD
        • Sub-Investigator:
          • Anthony Camuglia, MD
      • Heidelberg, Australia, 3084
        • Terminated
        • Warringal Hospital
      • Melbourne, Australia, 3004
        • Recruiting
        • The Alfred Hospital
        • Contact:
      • Newcastle, Australia
        • Recruiting
        • John Hunter Hospital
        • Contact:
          • Allan Davies, MD
        • Principal Investigator:
          • Allan Davies
      • Perth, Australia, 6150
        • Recruiting
        • Mount Hospital
        • Contact:
        • Principal Investigator:
          • Wen Yeow, MD
      • Sydney, Australia
        • Recruiting
        • North Shore Private Hospital
        • Contact:
          • Ravinay Bhindi
        • Principal Investigator:
          • Ravinay Bhinddi
    • New South Wales
      • Darlinghurst, New South Wales, Australia, 2010
        • Recruiting
        • St. Vincent's Hospital - Sydney
        • Contact:
        • Principal Investigator:
          • David Muller, MD
      • Newcastle, New South Wales, Australia, 2305
      • Sydney, New South Wales, Australia, 2109
        • Withdrawn
        • Macquarie University Hospital
    • Queensland
      • Auchenflower, Queensland, Australia, 4066
        • Recruiting
        • The Wesley Hospital
        • Contact:
          • Sam Haymen, MD
        • Principal Investigator:
          • Sam Haymen, MD
  • Belgium
      • Antwerp, Belgium, 2020
        • Recruiting
        • ZNA Middelheim
        • Contact:
          • Pierfranceso Agostoni, MD
        • Principal Investigator:
          • Pierfrancesco Agostoni, MD
      • Bruges, Belgium, 8000
      • Leuven, Belgium, 3000
        • Recruiting
        • UZ Leuven
        • Contact:
        • Principal Investigator:
          • Christophe Dubois, MD
  • France
      • Lille, France
        • Recruiting
        • CHU Lille
        • Contact:
          • Eric van Belle
        • Principal Investigator:
          • Eric van Belle
      • Lyon, France
        • Recruiting
        • Medipole Lyon-Villeurbanne
        • Contact:
          • Pierre-Yves Leroux, MD
        • Principal Investigator:
          • Pierre-Yves Leroux, MD
      • Massy, France
        • Recruiting
        • Hopital Prive - Jacques Cartier
        • Contact:
          • Thierry Lefevre
        • Principal Investigator:
          • Thierry Lefevre
      • Nantes, France
        • Recruiting
        • Centre Hospitalo-Universitaire de Nantes
        • Contact:
          • Vincent Letocart, MD
        • Principal Investigator:
          • Vincent Letocart, MD
      • Paris, France, 5015
        • Terminated
        • European Hospital George Pompidou
      • Pessac, France, 33600
      • Rennes, France, 35000
      • Saint-Denis, France
        • Recruiting
        • Centr Cardiologiqque du Nord
        • Contact:
          • Mohammed Nejjari
        • Principal Investigator:
          • Mohammed Nejjari
      • Strasbourg, France
        • Recruiting
        • CHRU Strasbourg
        • Contact:
          • Patrick Ohlmann, MD
        • Principal Investigator:
          • Patrick Ohlmann, MD
      • Toulouse, France, 31076
      • Toulouse, France
        • Recruiting
        • Rangueil University Hospital
        • Contact:
          • Lavie Badie, MD
        • Principal Investigator:
          • Lavie Badie, MD
    • Toulouse
      • Toulouse, Toulouse, France, 31400
        • Recruiting
        • Rangueil University Hospital
  • Germany
      • Bad Krozingen, Germany, 79189
        • Terminated
        • University Heart Center Freiburg - Bad Krozingen
      • Bonn, Germany, 53127
        • Recruiting
        • Universitaetsklinikum Bonn
        • Contact:
        • Contact:
        • Principal Investigator:
          • Georg Nickenig, MD
      • Dresden, Germany
        • Recruiting
        • Heart Center, University Hospital Dresden
        • Contact:
          • Axel Linke
        • Principal Investigator:
          • Axel Linke
      • Hamburg, Germany, 20246
        • Recruiting
        • Universitatsklink Hamburg-Eppendorf
        • Principal Investigator:
          • Niklas Schofer, MD
        • Contact:
          • Niklas Schofer, MD
      • Hamburg, Germany
        • Recruiting
        • Mediinisches Versorgungszentrum
        • Principal Investigator:
          • Joachim Schofer, MD
        • Contact:
          • Joachim Schofer, MD
      • Heidelberg, Germany
        • Terminated
        • University Hospital Heidelberg
      • Leipzig, Germany, 04289
        • Recruiting
        • Herzentrum Leipzig
        • Principal Investigator:
          • Tobias Kister, MD
        • Contact:
          • Tobias Kister, MD
      • Munich, Germany
        • Recruiting
        • Deutsches Herzzentrum Munchen
        • Contact:
          • Michael Joner, MD
        • Principal Investigator:
          • Michael Joner, MD
      • Rostock, Germany
        • Terminated
        • University Medicine Dept of Cardiology
      • Ulm, Germany, 89081
        • Recruiting
        • University Hospital Ulm
        • Contact:
        • Principal Investigator:
          • Wolfgang Rottbauer, MD
  • Poland
      • Gdansk, Poland
        • Recruiting
        • Medical University of Gdansk
        • Contact:
          • Radoslaw Targonski, MD
        • Principal Investigator:
          • Radoslaw Targonski, MD
      • Katowice, Poland, 40-635
        • Recruiting
        • Medical University of Silesia Hospital
        • Contact:
        • Principal Investigator:
          • Wojciech Wojakowski, MD
      • Poznan, Poland, 61-848
        • Terminated
        • University Hospital of Lord's Transfiguration
      • Warsaw, Poland, 02-097
        • Recruiting
        • Medical University of Warsaw
        • Contact:
          • Zenon Huczek, MD
          • Phone Number: +48 692 433 568
          • Email: zhuczek@wp.pl
      • Warsaw, Poland, 04-628
        • Recruiting
        • Institute of Cardiology
        • Contact:
        • Principal Investigator:
          • Adam Witkowski, MD
  • Singapore
      • Singapore, Singapore
        • Recruiting
        • National Heart Center Singapore
        • Contact:
          • Yeo Khung Keong, MD
        • Principal Investigator:
          • Yeo Khung Keong, MD
  • United Kingdom
      • Belfast, United Kingdom
        • Recruiting
        • Royal Victoria Hospital
        • Contact:
          • Colum Owens
        • Principal Investigator:
          • Colum Owens
      • Brighton, United Kingdom, BN2 5BE
        • Recruiting
        • Brighton and Sussex University Hospital
        • Contact:
      • Edinburgh, United Kingdom
        • Recruiting
        • Royal Infirmary of Edinburgh
        • Contact:
          • Miles Behan, MD
        • Principal Investigator:
          • Miles Behan, MD
      • Leeds, United Kingdom
        • Terminated
        • Leeds Teaching Hospitals NHS Trust
      • Leicester, United Kingdom
        • Terminated
        • University Hospitals of Leicester NHS Trust
      • London, United Kingdom, SE1 9RS
        • Recruiting
        • Guy's and St. Thomas' NHS Foundation Trust - St. Thomas Hospital
        • Contact:
          • Simon Redwood, MD
      • London, United Kingdom
        • Terminated
        • Barts Heart Center
      • Oxford, United Kingdom
        • Terminated
        • John Radcliffe

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • 1. Age ≥ 18 years 2. Moderate-severe or severe mitral regurgitation (≥ 3+) 3. Patient has New York Heart Association (NYHA) Functional Class II, III or ambulatory IV 4. Patient is under guideline directed medical therapy, as reviewed and confirmed by the local multidisciplinary Heart Team, for at least one month 5. Patient is high-risk for open-heart surgery based on the assessment of the multidisciplinary Heart Team using standard scoring systems and consideration of co-morbidities, frailty, and disability 6. Patient meets the anatomical criteria for HighLife valve 7. Patient is willing to participate in the study and provides signed informed consent

Exclusion Criteria:

  1. Any stroke/TIA within 30 days
  2. Severe symptomatic carotid stenosis (> 70% by non-invasive imaging)
  3. Active infections requiring antibiotic therapy
  4. Active ulcer or gastro-intestinal bleeding in the past 3 months
  5. History of bleeding diathesis, coagulopathy or refusal of future blood transfusion
  6. Patients in whom TEE is not feasible
  7. Patients who are pregnant or lactating, or plan to get pregnant in the next 12 months.
  8. Patient is unable to comply with the follow-up schedule and assessments
  9. Participation in another clinical investigation at the time of inclusion
  10. Patient has known allergies to the device components or contrast medium
  11. Patient cannot tolerate anticoagulation or antiplatelet therapy
  12. Patients with a life expectancy of less than 12 months due to non-cardiac conditions

  13. Patient had permanent pacemaker, or similar device with implantable cardiac leads (i.e. resynchronization therapy) within the last 3 months

    -

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Other: Single arm
Single arm, non-randomized
Device: HighLife Transcatheter Mitral Valve Replacement
Transcatheter Mitral Valve Replacement

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Device Safety
Time Frame: 30 days
Freedom from major adverse events
30 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

HighLife SAS

Collaborators

ICON plc

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 28, 2019

Primary Completion (Estimated)

December 15, 2026

Study Completion (Estimated)

December 15, 2031

Study Registration Dates

First Submitted

July 20, 2019

First Submitted That Met QC Criteria

July 20, 2019

First Posted (Actual)

July 23, 2019

Study Record Updates

Last Update Posted (Estimated)

September 15, 2025

Last Update Submitted That Met QC Criteria

September 9, 2025

Last Verified

September 1, 2025

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • HL-2018-01-TS Expanded EU/AU

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Mitral Regurgitation

Clinical Trials on HighLife Transcatheter Mitral Valve Replacement

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Saint Lucia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe